X4P 001

Drug Profile

X4P 001

Alternative Names: AMD-070; AMD11070; X4P 001 RD; X4P-001-IO; X4P001

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnorMED
  • Developer X4 Pharmaceuticals
  • Class Antineoplastics; Benzimidazoles; Diamines; Hydroquinones; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Immunodeficiency disorders
  • Phase II Renal cell carcinoma
  • Phase I/II Malignant melanoma
  • Phase I Solid tumours
  • Discontinued HIV-1 infections

Most Recent Events

  • 15 Jun 2018 Updated interim efficacy data from a phase II/III trial in Immunodeficiency disorders (WHIM Syndrome) presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 15 Jun 2018 X4 Pharmaceuticals plans to initiate phase III portion of a phase II/III trial for Immunodeficiency disorders (WHIM Syndrome) in the end of the year (NCT03005327)
  • 02 Jun 2018 Positive efficacy and safety data from a phase II portion of phase Ib/IIa trial in Renal cell carcinoma released by X4 Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top